Trial Profile

A Phase I/II, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LM 101 (Primary) ; Envafolimab; Rituximab; Toripalimab
Indications Colorectal cancer; Lymphoma; Non-Hodgkin's lymphoma; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors LaNova Medicines Limited

19 Dec 2024 Planned number of patients changed from 145 to 139.
19 Dec 2024 Planned End Date changed from 1 Aug 2025 to 11 Jan 2028.
19 Dec 2024 Planned primary completion date changed from 1 Dec 2024 to 11 Jan 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com